Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2007-08-21
2007-08-21
Bunner, Bridget (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S002600, C514S012200, C514S021800, C530S303000, C530S311000, C530S399000
Reexamination Certificate
active
10939111
ABSTRACT:
The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.
REFERENCES:
patent: 5741776 (1998-04-01), Clark et al.
patent: 5824642 (1998-10-01), Attie et al.
Clark, R., Recombinant human insulin-like growth factor 1 (IGF-1): risks and benefits of normalizing blood IGF-1 concentrations, 2004, Hormone Research, vol. 62, Supplement 1, pp. 93-100.
Zvi Laron. Somatomedin-1 (Recombinant) Insulin-like Growth Factor-1—Clinical Pharmacology and Potential Treatment of Endocrine and Metabolic Disorders. BioDrugs 1999, Jan. 11 (1): 55-70.
Clemmons DR et al., “Factors controlling blood concentration of somatomedin C”, 1984, Clin Endocrinol Metab 13:113-43.
Clemmons DR et al., “Evaluation of acromegaly by radioimmunoassay of somatomedin-c”, 1979, N Engl J Med 301:1138-42.
Clemmons DR et al., “Somatomedin-C/insulin-like growth factor I in acromegaly”, 1986, Olin Endocrinol Metal 15:629-51.
Juul, 2003, “Serum levels of insulin-like growth factor I and its binding proteins in health and disease”, GH and IGF Research 13: 113-170.
Liu, J-L and LeRoith, D, “Insulin-like growth factor 1 is essential for postnatal growth in response to growth hormone”, 1999, Endocrinology 140:5178-84.
Lupu, F et al., “Roles of growth hormone and insulin-like growth factor 1 in Mouse postnatal growth”, 2001, Dev Biol 229:141-62.
Salmon WD Jr. et al., “The journal of laboratory and clinical medicine”, 1957, J Lab Olin Med, 49:825-36.
Van Wyk JJ. The Somatomedins: biological actions and physiological control mechanisms in Hormonal Proteins and Peptides, ed CH Li, 12:81-175, Orlando, FL:Academic Press, this reference does not have a publication date.
Zhou, Y et al., A mammalian model for laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) 1997, Proc Natl Acad Sci. USA 94:13215-20.
Azcona et al., (1999), “Growth Response to rhIGF-1 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype”, Clinical Endocrinology, 51, pp. 787-792.
Borden Paula A.
Bozicevic Field & Francis LLP
Bunner Bridget
Dang Ian
Francis Carol L.
LandOfFree
Methods for treatment of insulin-like growth factor-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of insulin-like growth factor-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of insulin-like growth factor-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863320